tiprankstipranks
Trending News
More News >
Merck & Company (MRK)
NYSE:MRK
US Market
Advertisement

Merck & Company (MRK) Stock Forecast & Price Target

Compare
13,870 Followers
See the Price Targets and Ratings of:

MRK Analyst Ratings

Moderate Buy
17Ratings
Moderate Buy
10 Buy
7 Hold
0 Sell
Based on 17 analysts giving stock ratings to
Merck
& Company
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MRK Stock 12 Month Forecast

Average Price Target

$102.27
▲(21.78%Upside)
Based on 17 Wall Street analysts offering 12 month price targets for Merck & Company in the last 3 months. The average price target is $102.27 with a high forecast of $141.00 and a low forecast of $82.00. The average price target represents a 21.78% change from the last price of $83.98.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"74":"$74","91":"$91","108":"$108","125":"$125","142":"$142"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":141,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$141.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":102.27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$102.27</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":82,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$82.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[74,91,108,125,142],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,81.81,86.36307692307693,90.91615384615385,95.46923076923078,100.02230769230769,104.57538461538462,109.12846153846155,113.68153846153847,118.23461538461538,122.78769230769231,127.34076923076924,131.89384615384614,136.4469230769231,{"y":141,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,81.81,83.38384615384615,84.95769230769231,86.53153846153846,88.10538461538462,89.67923076923077,91.25307692307692,92.82692307692308,94.40076923076923,95.97461538461539,97.54846153846154,99.12230769230769,100.69615384615385,{"y":102.27,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,81.81,81.82461538461538,81.83923076923077,81.85384615384615,81.86846153846155,81.88307692307693,81.89769230769231,81.91230769230769,81.92692307692307,81.94153846153846,81.95615384615385,81.97076923076924,81.98538461538462,{"y":82,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":123.72,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.1,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.58,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.74,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.21,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.98,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.65,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.55,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.43,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.49,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.81,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$141.00Average Price Target$102.27Lowest Price Target$82.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on MRK
TipRanks AITipRanks
Not Ranked
TipRanks
$94
Buy
11.93%
Upside
Reiterated
07/23/25
Merck & Company's robust financial performance and attractive valuation are the primary strengths supporting its stock score. The strong pipeline and growth potential add to its long-term appeal, despite current challenges with Gardasil sales in China and tariff impacts.
Bank of America Securities Analyst forecast on MRK
Tim AndersonBank of America Securities
Bank of America Securities
$99
Buy
17.89%
Upside
Reiterated
07/23/25
Analysts Offer Insights on Healthcare Companies: Icon (NASDAQ: ICLR), Merck & Company (NYSE: MRK) and Thermo Fisher (NYSE: TMO)We reiterate our Buy rating and $99 PO on Merck (MRK).
Leerink Partners Analyst forecast on MRK
Daina GrayboschLeerink Partners
Leerink Partners
$115$92
Buy
9.55%
Upside
Reiterated
07/18/25
Merck & Company: Buy Rating Backed by Growth Prospects in Cardiopulmonary and Infectious Disease FranchisesWe believe several upcoming readouts could meaningfully expand Merck’s long-term revenue potential and reinvigorate interest in the stock, including enlicitide’s (oral PCSK9 inhibitor) trio of Ph3 lipid-lowering trials (likely in November), results from Winrevair in combined pre- and post-capillary pulmonary hypertension (CpcPH) due to heart failure with preserved ejection fraction (HFpEF) (Ph2 CADENCE 3Q25), and Keytruda + Welireg (HIF-2α inhibitor) in adjuvant renal cell carcinoma (RCC) (Ph3 LITESPARK-022 4Q26). The later two trials are high-risk/high-reward where success could drive outsized excitement. See within for further discussion of these programs.
BMO Capital Analyst forecast on MRK
Evan SeigermanBMO Capital
BMO Capital
$82
Hold
-2.36%
Downside
Reiterated
07/17/25
Merck & Co. Hold Rating: Balancing Promising HIV Pipeline with Competitive Challenges and Market Uncertainty
Wells Fargo Analyst forecast on MRK
Mohit BansalWells Fargo
Wells Fargo
$97
Hold
15.50%
Upside
Reiterated
07/17/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Harrow Health (NASDAQ: HROW), BridgeBio Pharma (NASDAQ: BBIO) and Merck & Company (NYSE: MRK)
Guggenheim Analyst forecast on MRK
Vamil DivanGuggenheim
Guggenheim
$108
Buy
28.60%
Upside
Reiterated
07/13/25
Guggenheim Sticks to Its Buy Rating for Merck & Company (MRK)
UBS
$105
Buy
25.03%
Upside
Reiterated
07/10/25
UBS Sticks to Their Buy Rating for Merck & Company (MRK)
Jefferies
$138$141
Buy
67.90%
Upside
Reiterated
07/10/25
Jefferies Sticks to Its Buy Rating for Merck & Company (MRK)
Morgan Stanley Analyst forecast on MRK
Terence FlynnMorgan Stanley
Morgan Stanley
$99$98
Hold
16.69%
Upside
Reiterated
07/10/25
Merck & Company's Strategic Acquisition of Verona Pharma: Balancing Long-Term Gains with Short-Term Financial Adjustments
Cantor Fitzgerald Analyst forecast on MRK
Carter GouldCantor Fitzgerald
Cantor Fitzgerald
$85$83
Hold
-1.17%
Downside
Reiterated
07/09/25
Cantor Fitzgerald Remains a Hold on Merck & Company (MRK)
Goldman Sachs Analyst forecast on MRK
Asad HaiderGoldman Sachs
Goldman Sachs
$99
Buy
17.89%
Upside
Reiterated
07/09/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
Bernstein
Hold
Reiterated
07/08/25
Merck & Company (MRK) Gets a Hold from Bernstein
J.P. Morgan Analyst forecast on MRK
Chris SchottJ.P. Morgan
J.P. Morgan
$130
Buy
54.80%
Upside
Reiterated
07/07/25
Merck & Company: Strong Growth Potential and Favorable Risk/Return Profile Amidst Keytruda's Performance and Diverse Portfolio
Berenberg Bank Analyst forecast on MRK
Luisa HectorBerenberg Bank
Berenberg Bank
$100
Buy
19.08%
Upside
Reiterated
07/01/25
Berenberg Bank Reaffirms Their Buy Rating on Merck & Company (MRK)
TD Cowen Analyst forecast on MRK
Steve ScalaTD Cowen
TD Cowen
$100
Hold
19.08%
Upside
Reiterated
06/26/25
TD Cowen Sticks to Their Hold Rating for Merck & Company (MRK)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on MRK
TipRanks AITipRanks
Not Ranked
TipRanks
$94
Buy
11.93%
Upside
Reiterated
07/23/25
Merck & Company's robust financial performance and attractive valuation are the primary strengths supporting its stock score. The strong pipeline and growth potential add to its long-term appeal, despite current challenges with Gardasil sales in China and tariff impacts.
Bank of America Securities Analyst forecast on MRK
Tim AndersonBank of America Securities
Bank of America Securities
$99
Buy
17.89%
Upside
Reiterated
07/23/25
Analysts Offer Insights on Healthcare Companies: Icon (NASDAQ: ICLR), Merck & Company (NYSE: MRK) and Thermo Fisher (NYSE: TMO)We reiterate our Buy rating and $99 PO on Merck (MRK).
Leerink Partners Analyst forecast on MRK
Daina GrayboschLeerink Partners
Leerink Partners
$115$92
Buy
9.55%
Upside
Reiterated
07/18/25
Merck & Company: Buy Rating Backed by Growth Prospects in Cardiopulmonary and Infectious Disease FranchisesWe believe several upcoming readouts could meaningfully expand Merck’s long-term revenue potential and reinvigorate interest in the stock, including enlicitide’s (oral PCSK9 inhibitor) trio of Ph3 lipid-lowering trials (likely in November), results from Winrevair in combined pre- and post-capillary pulmonary hypertension (CpcPH) due to heart failure with preserved ejection fraction (HFpEF) (Ph2 CADENCE 3Q25), and Keytruda + Welireg (HIF-2α inhibitor) in adjuvant renal cell carcinoma (RCC) (Ph3 LITESPARK-022 4Q26). The later two trials are high-risk/high-reward where success could drive outsized excitement. See within for further discussion of these programs.
BMO Capital Analyst forecast on MRK
Evan SeigermanBMO Capital
BMO Capital
$82
Hold
-2.36%
Downside
Reiterated
07/17/25
Merck & Co. Hold Rating: Balancing Promising HIV Pipeline with Competitive Challenges and Market Uncertainty
Wells Fargo Analyst forecast on MRK
Mohit BansalWells Fargo
Wells Fargo
$97
Hold
15.50%
Upside
Reiterated
07/17/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Harrow Health (NASDAQ: HROW), BridgeBio Pharma (NASDAQ: BBIO) and Merck & Company (NYSE: MRK)
Guggenheim Analyst forecast on MRK
Vamil DivanGuggenheim
Guggenheim
$108
Buy
28.60%
Upside
Reiterated
07/13/25
Guggenheim Sticks to Its Buy Rating for Merck & Company (MRK)
UBS
$105
Buy
25.03%
Upside
Reiterated
07/10/25
UBS Sticks to Their Buy Rating for Merck & Company (MRK)
Jefferies
$138$141
Buy
67.90%
Upside
Reiterated
07/10/25
Jefferies Sticks to Its Buy Rating for Merck & Company (MRK)
Morgan Stanley Analyst forecast on MRK
Terence FlynnMorgan Stanley
Morgan Stanley
$99$98
Hold
16.69%
Upside
Reiterated
07/10/25
Merck & Company's Strategic Acquisition of Verona Pharma: Balancing Long-Term Gains with Short-Term Financial Adjustments
Cantor Fitzgerald Analyst forecast on MRK
Carter GouldCantor Fitzgerald
Cantor Fitzgerald
$85$83
Hold
-1.17%
Downside
Reiterated
07/09/25
Cantor Fitzgerald Remains a Hold on Merck & Company (MRK)
Goldman Sachs Analyst forecast on MRK
Asad HaiderGoldman Sachs
Goldman Sachs
$99
Buy
17.89%
Upside
Reiterated
07/09/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
Bernstein
Hold
Reiterated
07/08/25
Merck & Company (MRK) Gets a Hold from Bernstein
J.P. Morgan Analyst forecast on MRK
Chris SchottJ.P. Morgan
J.P. Morgan
$130
Buy
54.80%
Upside
Reiterated
07/07/25
Merck & Company: Strong Growth Potential and Favorable Risk/Return Profile Amidst Keytruda's Performance and Diverse Portfolio
Berenberg Bank Analyst forecast on MRK
Luisa HectorBerenberg Bank
Berenberg Bank
$100
Buy
19.08%
Upside
Reiterated
07/01/25
Berenberg Bank Reaffirms Their Buy Rating on Merck & Company (MRK)
TD Cowen Analyst forecast on MRK
Steve ScalaTD Cowen
TD Cowen
$100
Hold
19.08%
Upside
Reiterated
06/26/25
TD Cowen Sticks to Their Hold Rating for Merck & Company (MRK)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Merck & Company

1 Month
xxx
Success Rate
10/14 ratings generated profit
71%
Average Return
+1.41%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +1.41% per trade.
3 Months
xxx
Success Rate
9/14 ratings generated profit
64%
Average Return
+1.34%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +1.34% per trade.
1 Year
Daina GrayboschLeerink Partners
Not Ranked
Success Rate
26/48 ratings generated profit
54%
Average Return
+4.98%
reiterated a buy rating 7 days ago
Copying Daina Graybosch's trades and holding each position for 1 Year would result in 54.17% of your transactions generating a profit, with an average return of +4.98% per trade.
2 Years
xxx
Success Rate
13/18 ratings generated profit
72%
Average Return
+10.28%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 72.22% of your transactions generating a profit, with an average return of +10.28% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MRK Analyst Recommendation Trends

Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
2
2
2
3
4
Buy
25
28
21
24
20
Hold
17
19
15
26
23
Sell
0
0
0
1
1
Strong Sell
0
0
0
0
0
total
44
49
38
54
48
In the current month, MRK has received 24 Buy Ratings, 23 Hold Ratings, and 1 Sell Ratings. MRK average Analyst price target in the past 3 months is 102.27.
Each month's total comprises the sum of three months' worth of ratings.

MRK Financial Forecast

MRK Earnings Forecast

Next quarter’s earnings estimate for MRK is $2.02 with a range of $1.88 to $2.12. The previous quarter’s EPS was $2.22. MRK beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.13% of the time in the same period. In the last calendar year MRK has Preformed in-line its overall industry.
Next quarter’s earnings estimate for MRK is $2.02 with a range of $1.88 to $2.12. The previous quarter’s EPS was $2.22. MRK beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.13% of the time in the same period. In the last calendar year MRK has Preformed in-line its overall industry.

MRK Sales Forecast

Next quarter’s sales forecast for MRK is $15.90B with a range of $15.55B to $16.81B. The previous quarter’s sales results were $15.62B. MRK beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.59% of the time in the same period. In the last calendar year MRK has Preformed in-line its overall industry.
Next quarter’s sales forecast for MRK is $15.90B with a range of $15.55B to $16.81B. The previous quarter’s sales results were $15.62B. MRK beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.59% of the time in the same period. In the last calendar year MRK has Preformed in-line its overall industry.

MRK Stock Forecast FAQ

What is MRK’s average 12-month price target, according to analysts?
Based on analyst ratings, Merck & Company’s 12-month average price target is 102.27.
    What is MRK’s upside potential, based on the analysts’ average price target?
    Merck & Company has 21.78% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MRK a Buy, Sell or Hold?
          Merck & Company has a consensus rating of Moderate Buy which is based on 10 buy ratings, 7 hold ratings and 0 sell ratings.
            What is Merck & Company’s price target?
            The average price target for Merck & Company is 102.27. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $141.00 ,the lowest forecast is $82.00. The average price target represents 21.78% Increase from the current price of $83.98.
              What do analysts say about Merck & Company?
              Merck & Company’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.
                How can I buy shares of MRK?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis